NXTM Profile
NxStage
Medical, Inc., trading under the ticker symbol NXTM, was a medical
technology company that developed and marketed products for the
treatment of kidney disease and other chronic conditions. The company
was headquartered in Lawrence, Massachusetts.
NxStage Medical's
products and solutions included hemodialysis systems, peritoneal
dialysis systems, and other products and accessories used in the
treatment of kidney disease. The company's mission was to improve the
quality of life for patients with kidney disease by providing
innovative products and services that enabled more frequent and
convenient dialysis treatments.
In 2018, NxStage Medical was
acquired by Fresenius Medical Care, a global provider of dialysis
products and services, for approximately $2 billion, and the company
was delisted from the NASDAQ stock exchange.
Prior to its
acquisition, as of its most recent financial filings, NxStage Medical
had revenues of approximately $394 million and employed over 3,000
professionals across its various operations worldwide. The company
faced competition from other medical technology companies operating in
the kidney disease and dialysis products industries.
Investors
who held NXTM stock should have received compensation from the
acquisition. Investors who are interested in the medical technology
industry may want to research other publicly traded companies in the
sector, evaluate their financial performance, competitive position,
and growth
|
